Influence of Motor Proteins on Muscle Atrophy in Cancer Patients

Cancer Clinical Trial

Official title:

Influence of Motor Proteins on Muscle Atrophy in Cancer Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03551990
• Other study ID #: EMS Tumor Motor Proteins
• Status: Recruiting
• Phase: N/A
• Start date: May 31, 2017
• Est. completion date: June 2022

Study information

• Verified date: May 2018
• Source: University of Erlangen-Nürnberg Medical School
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to investigate the effect of exercise in form of whole-body electromyostimulation (WB-EMS) on early tumor-induced muscular dysfunction. It is anticipated to gain detailed knowledge about composition and metabolism of skeletal muscle cells, and single muscle fiber functionality. To determine key factors leading to impaired force generation and thus decreased muscle strength in cancer patients who are suspected to develop or already show early signs of tumor cachexia is crucial for the establishment of effective cancer treatment. Comparative analysis of skeletal muscle biopsies taken from the abdomen of patients during indicated surgeries will be conducted. The patients will be allocated to the following study groups: a) Study group 1: Patients without cancer, b) Study group 2: Patients with solid tumors who did not perform physical training and c) Study group 3: Patients with solid tumors who executed physical training in form of WB-EMS. The investigation can help to understand skeletal muscle physiology under exercise and to get a better insight into the effects of physical training on early-stage muscle atrophy, both on cellular and molecular level. Initially, it is planned to identify the inflammation and nutrition status of the patients, and to determine skeletal muscle strength. It is anticipated to explore muscle protein composition, particularly myosin to actin ratio and their interaction. Biochemical analysis and the examination of the cellular ultra-structure should enhance the knowledge about the key mechanisms controlling the contractile apparatus of single muscle fibers in order to determine the quality of muscle force. Taken together, these investigations will help to better understand muscle atrophy in advanced cancer patients, and might support the development of targeted anti-cachectic therapies, that can be applied already in early phases of the tumor disease to significantly improve the patients' prognosis and their quality of life.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 420
• Est. completion date: June 2022
• Est. primary completion date: December 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients = 18 years

• Solid pancreatic, colorectal, esophageal, gastric and liver tumors under oncological treatment

• Karnofsky performance index between 50 and 100

• Loss of body weight (= 2 % and < 5 %, weight before the illness and at study entry)

• Distinct decrease in muscle force

• Indication for surgery proximal to the M. rectus abdominis

• Intervention Group must have an at least 8-week waiting period until the surgery (to conduct WB-EMS)

Exclusion Criteria:

• Participation in other nutrition or exercise intervention studies

• Study-independent exercise more than once a week

• Ingestion of anabolic or dietary supplements

• Occurrence of heavy cardio-vascular events

• Epilepsy and other severe neurological disorders

• Skin lesions in the area of the electrodes

• Conductive materials or electronical implants in the body (that do not allow electromyostimulation)

• Pregnancy

• Chronic diseases (e.g. HIV or Hepatitis C/D/E)

• Rejection of a muscle biopsy

Related Conditions & MeSH terms

• Atrophy
• Cancer
• Muscle Atrophy
• Muscular Atrophy

Intervention

Procedure:
• whole-body electromyostimulation WB-EMS
Patients of the WB-EMS group will perform whole-body electromyostimulation (WB-EMS) training sessions twice a week over a period of 8 weeks. To allow muscle recovery a break of at least 2 days between the sessions will be scheduled. To adapt the patients to the WB-EMS intervention, the training duration will be gradually increased (week 1, 12 min; increase of 2 min/week; week 5-8, 20 min). WB-EMS training sessions will include light physical exercises according to a video tutorial and individually supervised by certified physio therapists.

Locations

Country	Name	City	State
Germany	Hector-Center for Nutrition, Exercise and Sports	Erlangen	Bavaria

Sponsors (1)

Lead Sponsor	Collaborator
University of Erlangen-Nürnberg Medical School

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Differences in Myosin:Actin ratio	Myosin:Actin ratio in the muscle biopsies assessed by protein analysis via Western Blotting.	8 weeks
Primary	Differences in Myosin isoforms	The Myosin isoforms in the muscle biopsies will be determined by protein expression analysis via Western Blotting.	8 weeks
Primary	Differences in cellular ultra structures	Cellular ultra structures in the muscle biopsies will be examined using multi-photon microscopy.	8 weeks
Primary	Differences in Force development and Calcium 2+ sensitivity of single muscle fibers	Force development and Calcium 2+ sensitivity of single muscle fibers from the muscle biopsies will be assessed by in situ biomechanical recording.	8 weeks
Primary	Differences in activation of involved signaling pathways	Signaling pathways that regulate muscle atrophy will be analyzed by examining protein expression and modification (Western Blotting), and gene expression (quantitative PCR) in the muscle biopsies.	8 weeks
Secondary	Differences in inflammatory status	Pro-inflammatory cytokines	0 week
Secondary	Differences in Nutritional risk	Nutritional Risk Screening-2002	0 week